Dihydrosanguinarine: A Review of Its Pharmacology, Structure–Activity Relationship, Toxicity, Pharmacokinetics, and Clinical Prospects
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27114852 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Xiaoqi Yin und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China. Hauptthemen laut MEDLINE: Benzophenanthridines, Isoquinolines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 129 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Dihydrosanguinarine (DHSA) is a naturally occurring benzo[c]phenanthridine alkaloid primarily isolated from plants of the Papaveraceae family. DHSA exhibits broad pharmacological activities, including antitumor, anti-inflammatory, hypoglycemic, neuroprotective, analgesic, anxiolytic, antiarrhythmic, and antimicrobial effects. Mechanistically, DHSA regulates multiple signaling pathways and molecular targets, including TMEM16A, p53, Ras/Raf/MEK/ERK, PI3K/AKT, NF-κB, PPARγ, GABAA receptors, and voltage-gated sodium channels. Compared with its biosynthetic precursor sanguinarine (SA), DHSA exhibits a comparatively favorable safety profile while retaining considerable biological activity. Pharmacokinetic studies further suggest that DHSA possesses acceptable membrane permeability, gastrointestinal absorption potential, enterohepatic circulation characteristics, and sustained systemic exposure. In addition, structure–activity relationship (SAR) and electrostatic surface potential (ESP) analyses indicate that the chemically accessible C6 position may provide opportunities for rational structural optimization. Nevertheless, the clinical translation of DHSA still faces several challenges. Therefore, this review systematically summarizes the physicochemical properties, pharmacological activities, molecular mechanisms, SAR characteristics, ESP distribution, toxicity, pharmacokinetic behavior, and clinical prospects of DHSA, aiming to provide a theoretical basis for its future drug development and translational application.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
- New Cornerstone Science Laboratory, Tsinghua University-Peking University Joint Center for Life Sciences, School of Basic Medical Sciences, Tsinghua University, Beijing 100084, China.
- School of Medical Technology, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
- Department of Anatomy, School of Basic Medicine Sciences, Tianjin Medical University, Tianjin 300070, China.
- Research Center for Infectious Diseases, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
- School of Public Health, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
ORCID-Profile: Long Yang
Zitieren
APA
Yin, X., Cao, Y., Fang, C., Zhang, C., Yang, J., Yu, M., Cheng, G., & Yang, L. (2026). Dihydrosanguinarine: A Review of Its Pharmacology, Structure–Activity Relationship, Toxicity, Pharmacokinetics, and Clinical Prospects. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27114852
Vancouver
Yin X, Cao Y, Fang C, Zhang C, Yang J, Yu M, et al. Dihydrosanguinarine: A Review of Its Pharmacology, Structure–Activity Relationship, Toxicity, Pharmacokinetics, and Clinical Prospects. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27114852
BibTeX
@article{Yin2026,
author = {Yin, Xiaoqi and Cao, Yingyi and Fang, Chuxuan and Zhang, Ce and Yang, Jiaming and Yu, Mingyu and Cheng, Gong and Yang, Long},
title = {Dihydrosanguinarine: A Review of Its Pharmacology, Structure–Activity Relationship, Toxicity, Pharmacokinetics, and Clinical Prospects},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27114852}
}
EUVIMED